title: Absence of plasma prostacyclin stimulating activity deficiency in hemolytic uremic syndrome.
abstract: We compared the effect of plasma from 19 children with hemolytic uremic syndrome (HUS) on prostacyclin (PGI2) production by fresh rat aortic rings to the effect of plasma from 17 age- and sex-matched normal children, taking into account the PGI2 baseline aortic production (PGI2 release in presence of buffer, 21 determinations). After 10, 20, 30, 40, and 60 minutes incubation of rat aortic tissue with either plasma or buffer, the presence of PGI2 was studied by measuring by radioimmunoassay (RIA) the concentration of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha). 6-keto-PGF1 alpha production increased with time in the two groups of plasma samples and in the presence of buffer, but 6-keto-PGF1 alpha production (ng/mg dried tissue) after 30 minutes incubation and mean 6-keto-PGF1 alpha production (slope of regression line, ng/mg/min) were significantly (P less than 0.01) lower in the presence of normal plasma compared with buffer, and significantly (P less than 0.01) higher in the presence of HUS plasma compared with normal plasma. There was no significant difference between buffer and HUS plasma. We conclude that, under our experimental conditions, normal plasma had an inhibitory activity on 6-keto-PGF1 alpha production by rat aorta. This inhibitory activity was absent in HUS plasma.
authors.forename: N
authors.initials: N
authors.lastname: Schlegel
authors.forename: J
authors.initials: J
authors.lastname: Maclouf
authors.forename: C
authors.initials: C
authors.lastname: Loirat
authors.forename: L
authors.initials: L
authors.lastname: Drouet
authors.forename: R
authors.initials: R
authors.lastname: Marotte
authors.forename: P Y
authors.initials: PY
authors.lastname: Scarabin
authors.forename: H
authors.initials: H
authors.lastname: Mathieu
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D001011:Aorta / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D011464:Epoprostenol / Q000096:biosynthesis*; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000097:blood*; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D008297:Male; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol